Viewing data from:

ZAVZPRET

NDA

ZAVEGEPANT HYDROCHLORIDE | N216386 | PFIZER INC

1 strength1 unique patent1 unique exclusivity

Patent Timeline

1 unique patent, 1 exclusivity by expiration date

Active (1)TodayExclusivity

2027

2028

2029

2030

2031

2032

2033

2034

Today

8481546

Jun. 26, 2034

NCE

Mar. 9, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$190.13

per ea

Lowest NADAC/Unit

$190.13

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00069350002ZAVZPRET 10 MG NASAL SPRAY	$190.13	EA	Brand	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (1 FSS, 1 Big4)

Lowest Price

$841.45

Highest Price

$1114.09

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00069-3500-02ZAVZPRET 10MG NASAL SPRAY	$1114.09	FSS	Pfizer Inc.	06/30/2029
00069-3500-02ZAVZPRET 10MG NASAL SPRAY	$841.45	Big4	Pfizer Inc.	06/30/2029

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Zavzpret (2024)

Total Spending

$8.9M

Total Claims

7,727

Beneficiaries

2,783

Avg Cost/Unit

$177.46

Spending Trend

$2.3M(2023)→$8.9M(2024)

YoY Change:-8.9%

5yr CAGR:-8.9%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs

5 active API suppliers hold Drug Master Files for this ingredient.

MOEHS IBERICA SLZAVEGEPANT

DMF 414702025

XUZHOU WANBANG JINQIAO PHARMA CO LTDZAVEGEPANT HYDROCHLORIDE

DMF 426162025

FORMOSA LABORATORIES INCZAVEGEPANT HYDROCHLORIDE

DMF 429142025

CIPLA LTDZAVEGEPANT HYDROCHLORIDE

DMF 434982026

MSN LIFE SCIENCES PRIVATE LTDZAVEGEPANT HYDROCHLORIDE

DMF 438082026

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Aug 5, 2025	SUPPL -7	View Letter (PDF)
Mar 25, 2025	SUPPL -5	View Letter (PDF)
Mar 10, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 10MG BASE/SPRAY

RLD

1 patent1 exclusivity▴

SPRAY, METERED;NASAL | Approved: Mar 9, 2023

Patents (1) · 1 use code

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8481546	Jun 26, 2034	—	Yes	Yes		—

Exclusivities (1)

Code	Date	Status
NCE	Mar 9, 2028	Active